Your browser doesn't support javascript.
loading
Combining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trial.
Sánchez-Marteles, Marta; Garcés-Horna, Vanesa; Morales-Rull, José Luís; Casado, Jesús; Carrera-Izquierdo, Margarita; Conde-Martel, Alicia; Dávila-Ramos, Melitón Francisco; Llácer, Pau; Salamanca-Bautista, Prado; Ruiz, Raúl; Aramburu-Bodas, Oscar; Formiga, Francesc; Manzano, Luís; Trullàs, Joan Carles.
Afiliação
  • Sánchez-Marteles M; Internal Medicine Department, Hospital Clínico Universitario "Lozano Blesa," Calle de San Juan Bosco, Zaragoza, Spain; Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain. Electronic address: marta.sanchez15@yahoo.es.
  • Garcés-Horna V; Internal Medicine Department, Hospital Clínico Universitario "Lozano Blesa," Calle de San Juan Bosco, Zaragoza, Spain; Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
  • Morales-Rull JL; Internal Medicine Department, Heart Failure Unit, Hospital Universitari Arnau de Villanova, Institut de Recerca Biomédica (IRBLleida), Avinguda Alcalde Rovira Roure, Lleida, Spain.
  • Casado J; Internal Medicine Department, Hospital Universitario de Getafe, Carretera de Madrid-Toledo, Madrid, Spain.
  • Carrera-Izquierdo M; Internal Medicine Department, Complejo Hospitalario de Soria, Paseo Santa Bárbara, Soria, Spain.
  • Conde-Martel A; Internal Medicine Department, Hospital Universitario de Gran Canaria Dr. Negrín, C. Pl. Barranco de la Ballena, Las Palmas de Gran Canaria, Spain.
  • Dávila-Ramos MF; Internal Medicine Department, Hospital Universitario Nuestra Señora de la Candelaria, Carretera General del Rosario, Santa Cruz de Tenerife, Spain.
  • Llácer P; Internal Medicine Department, Hospital de Manises, Avinguda de la Generalitat Valenciana, Manises, Valencia, Spain.
  • Salamanca-Bautista P; Internal Medicine Department, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Avenida Dr. Fedriani, Sevilla, Spain.
  • Ruiz R; Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.
  • Aramburu-Bodas O; Internal Medicine Department, Hospital Universitario Virgen Macarena, Universidad de Sevilla, Avenida Dr. Fedriani, Sevilla, Spain.
  • Formiga F; Internal Medicine Department, Hospital Universitari de Bellvitge, IDIBELL, Carrer de la Feixa Llarga, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Manzano L; Internal Medicine Department, Hospital Universitario Ramón y Cajal, IRYCIS, Universidad de Alcalá, Madrid, Spain.
  • Trullàs JC; Internal Medicine Department, Hospital d'Olot i Comarcal de la Garrotxa, Avinguda dels Països Catalans Olot, Girona, Spain; Tissue Repair and Regeneration Laboratory (TR2Lab), Institut de Recerca i Innovació en Ciències de la Vida i de la Salut a la Catalunya Central (IrisCC), Ctra. de Roda, Barcelo
JACC Heart Fail ; 12(10): 1719-1730, 2024 Oct.
Article em En | MEDLINE | ID: mdl-38934966
ABSTRACT

BACKGROUND:

The addition of hydrochlorothiazide (HCTZ) to furosemide in the CLOROTIC (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure) trial improved the diuretic response in patients with acute heart failure (AHF).

OBJECTIVES:

This work aimed to evaluate if these results differ across the spectrum of left ventricular ejection fraction (LVEF).

METHODS:

This post hoc analysis of the randomized, double-blind, placebo-controlled CLOROTIC trial enrolled 230 patients with AHF to receive either HCTZ or a placebo in addition to an intravenous furosemide regimen. The influence of LVEF on primary and secondary outcomes was evaluated.

RESULTS:

The median LVEF was 55% 166 (72%) patients had LVEF >40%, and 64 (28%) had LVEF ≤40%. Patients with a lower LVEF were younger, more likely to be male, had a higher prevalence of ischemic heart disease, and had higher natriuretic peptide levels. The addition of HCTZ to furosemide was associated with the greatest weight loss at 72 of 96 hours, better metrics of diuretic response, and greater 24-hour diuresis compared with placebo, with no significant differences according to the LVEF category (using 2 LVEF cutoff points 40% and 50%) or LVEF as a continuous variable (all P values were insignificant). There were no significant differences observed with the addition of HCTZ in terms of mortality, rehospitalizations, or safety endpoints (impaired renal function, hyponatremia, and hypokalemia) among the 2 LVEF groups (all P values were insignificant).

CONCLUSIONS:

Adding HCTZ to intravenous furosemide seems to be effective strategy for improving diuretic response in AHF without treatment effect modification according to baseline LVEF. (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure [CLOROTIC], NCT01647932; Randomized, double blinded, multicenter study, to asses Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics vs Loop diuretics with placebo in Patients With Decompensated, EudraCT Number 2013-001852-36).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Volume Sistólico / Inibidores de Simportadores de Cloreto de Sódio / Inibidores de Simportadores de Cloreto de Sódio e Potássio / Furosemida / Insuficiência Cardíaca / Hidroclorotiazida Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JACC Heart Fail Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Volume Sistólico / Inibidores de Simportadores de Cloreto de Sódio / Inibidores de Simportadores de Cloreto de Sódio e Potássio / Furosemida / Insuficiência Cardíaca / Hidroclorotiazida Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JACC Heart Fail Ano de publicação: 2024 Tipo de documento: Article